Printer Friendly

CANADIAN LICENSE FOR NEW NEUROLOGY DRUG ACQUIRED BY DEPRENYL RESEARCH LIMITED FROM LABORATOIRE L. LAFON OF FRANCE

 TORONTO, Nov. 19 ~PRNewswire~ -- Laboratoire L. Lafon of Paris, France and Deprenyl Research Limited (TSE: DEP; NASDAQ: DEPLF) announced today that they have concluded an agreement whereby Deprenyl Research has acquired an exclusive license to market Modafinil in Canada.
 Modafinil, recently approved in France, is a new drug for narcolepsy, a disorder which affects an estimated 26,000 Canadians, according to Sleep-Wake Disorders Canada, a national patient group. The drug received extensive testing in Europe including testing on French military personnel during the Gulf war. Modafinil regulates wakefulness without cardiovascular effects in patients with sleeping disorders. It is an original new drug with a novel mechanism of action entirely unrelated to amphetamines or methylphenidate (Ritalin R). Modafinil has been shown to have a good safety profile and a low abuse potential.
 Dr. Roger Mailhot, Deprenyl's vice president-scientific affairs, indicated that Deprenyl expects to submit the drug to Canadian regulatory authorities within the next ninety days.
 Deprenyl Research Limited is a Canadian pharmaceutical company which currently markets three neurologic drugs for Parkinson's disease. It is carrying out and sponsoring research in Alzheimer's disease, epilepsy, multiple sclerosis and other neurologic disorders. The company recently launched in Canada four of its drugs from its dermatologic division through its affiliate Lipopharm Inc. of Montreal, Quebec.
 -0- 11~19~92
 ~CONTACTS: Martin Barkin, M.D., president & CEO or Deborah Worobec, investor relations, 416-537-4372, fax 416-537-1653, both of Deprenyl Research, or Jim Tolan, senior vice president of O'Connor Biro & Associates, 708-498-2284, fax 708-498-3144, for Deprenyl Research~
 (DEP DEPLF)


CO: Deprenyl Research Limited ST: Ontario IN: MTC SU: LIC

TM -- NY008 -- 2703 11~19~92 09:03 EST
COPYRIGHT 1992 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1992 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Nov 19, 1992
Words:271
Previous Article:NUCLEAR METALS, INC. ANNOUNCES FOURTH QUARTER FISCAL 1992 RESULTS
Next Article:TADIRAN EARNED $8.3 MILLION DURING 1992s THIRD QUARTER
Topics:


Related Articles
DEPRENYL RESEARCH CO-CHAIRMAN SENDS LETTER TO SHAREHOLDERS
DEPRENYL RESEARCH NOTES NO CHANGE IN COMPANY TO ACCOUNT FOR CURRENT PRESSURES ON SHARE PRICE
DEPRENYL ANNOUNCES AGREEMENT TO ACQUIRE CONTROL OF LIPOPHARM
DEPRENYL ACQUIRES CONTROL OF QUEBEC-BASED LIPOPHARM INC.
BONE HEALTH INC. & DEPRENYL RESEARCH LIMITED ANNOUNCE SMITHKLINE BEECHAM HAS TRANSFERRED BACK TO LUNAR CORP. ALL ITS RIGHTS TO ONE-ALPHA D-2
DEPRENYL RESEARCH LTD. RECEIVES NOTIFICATION FROM LUNAR OF TAKEDA'S INTENT TO TERMINATE LICENSE AGREEMENT
CEPHALON LICENSES NOVEL PRODUCT TO TREAT NARCOLEPSY FROM LABORATOIRE L. LAFON
CEPHALON BEGINS MODAFINIL CLINICAL TRIAL IN UNITED STATES; EXPANDS MARKETING TERRITORY TO U.K. AND IRELAND
Draxis Files New Drug Submission for Modafinil in Canada
Anesta Corp. Signs Actiq Partnership For France

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters